Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 6;13(16):3985.
doi: 10.3390/cancers13163985.

Survival and Disease Recurrence in Patients with Duodenal Neuroendocrine Tumours-A Single Centre Cohort

Oddry Folkestad  1   2 , Hans H Wasmuth  3 , Patricia Mjønes  3   4 , Reidun Fougner  5 , Øyvind Hauso  3   6 , Reidar Fossmark  3   6
Affiliations

Survival and Disease Recurrence in Patients with Duodenal Neuroendocrine Tumours-A Single Centre Cohort

Oddry Folkestad et al. Cancers (Basel). .

Abstract

Background: Duodenal neuroendocrine tumours (D-NETs) are rare but increasingly diagnosed. This study aimed to assess the overall survival and recurrence rate among patients treated for D-NETs.

Methods: Patients with D-NETs were retrospectively reviewed with a median follow-up time of 4.8 years (range 0.0-17.2 years).

Results: A total of 32 patients with median age 68.0 years were identified. Fifteen patients underwent surgery while ten patients underwent endoscopic treatment. Mean estimated overall survival for the entire population was 12.1 years (95% CI 9.5-14.7 years), while 5-year overall survival was 81.3%. Tumour grade G1 was associated with longer mean estimated survival compared to G2 tumours (13.2 years versus 4.4 years, p = 0.010). None of the 23 patients who underwent presumed radical endoscopic or surgical resection had disease recurrence during follow-up. Tumours <10 mm could be treated endoscopically whereas a high proportion of patients with tumours 10-20 mm should be considered for surgery.

Conclusion: Patients with D-NETs had long overall survival, and mortality was more influenced by other diseases. Both endoscopic and surgical resections were effective as no recurrences were diagnosed during follow-up.

Keywords: duodenum; endoscopy; neuroendocrine tumour; outcome; recurrence; surgery; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Yao J.C., Hassan M.M., Phan A.T., Dagohoy C.G., Leary C.C., Mares J.E., Abdalla E.K., Fleming J.B., Vauthey J.-N., Rashid A., et al. One Hundred Years after “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States. J. Clin. Oncol. 2008;26:3063–3072. doi: 10.1200/JCO.2007.15.4377. - DOI - PubMed
    1. Modlin I.M., Lye K.D., Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934–959. doi: 10.1002/cncr.11105. - DOI - PubMed
    1. Fitzgerald T.L., Dennis S.O., Kachare S.D., Vohra N.A., Zervos E.E. Increasing incidence of duodenal neuroendocrine tumors: Incidental discovery of indolent disease? J. Gastrointest. Surg. 2015;158:466–471. doi: 10.1016/j.surg.2015.03.042. - DOI - PubMed
    1. Peery A.F., Dellon E.S., Lund J., Crockett S., McGowan C.E., Bulsiewicz W.J., Gangarosa L.M., Thiny M.T., Stizenberg K., Morgan D.R., et al. Burden of Gastrointestinal Disease in the United States: 2012 Update. Gastroenterology. 2012;143:1179–1187.e3. doi: 10.1053/j.gastro.2012.08.002. - DOI - PMC - PubMed
    1. Soga J. Endocrinocarcinomas (carcinoids and their variants) of the duodenum. An evaluation of 927 cases. J. Exp. Clin. Cancer Res. 2003;22:349–363. - PubMed

LinkOut - more resources